Three anti-tumor necrosis factor-alpha (anti-TNFα) therapies are approved for rheumatoid arthritis (RA) by the US Food and Drug Administration: infliximab (Remicade®), adalimumab (Humira®), and etanercept (Enbrel®). Here, TNF is linked to rheumatoid arthritis.